Related Experiment Videos
Clomiphene-associated combined hyperlipidemia: a case report
Melissa J Gillett1, John R Burnett, Doreen Yeap
1Department of Core Clinical Pathology and Biochemistry, Path West Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia, Australia. melissa.gillett@health.wa.gov.au
The Journal of Reproductive Medicine
|August 18, 2006
Summary
Clomiphene can worsen lipid disorders, particularly in women with pre-existing conditions. Monitoring lipid profiles before and during clomiphene therapy is recommended for at-risk patients.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Reproductive Medicine
Background:
- Clomiphene citrate is a widely used ovulation induction agent.
- Estrogen analogs are known to cause hypertriglyceridemia.
- Limited data exists on clomiphene's impact on human lipid metabolism.
Observation:
- A patient with obesity and polycystic ovary syndrome experienced significant lipid profile deterioration during clomiphene therapy.
- The patient had a history of amenorrhea and baseline lipids suggesting an underlying lipid disorder.
- Lipid levels improved upon discontinuation of clomiphene without lipid-lowering medication.
Findings:
- Clomiphene use can exacerbate underlying lipid abnormalities.
- Familial dysbetalipoproteinemia was diagnosed in the patient.
- Hyperlipidemia is a potential complication of clomiphene therapy.
Implications:
- Caution is advised when prescribing clomiphene to patients with known dyslipidemia.
- Pre-treatment lipid level assessment is recommended for women with risk factors for lipid disorders undergoing ovulation induction.
- Further research is needed to elucidate the mechanisms of clomiphene's effect on lipid metabolism.